Differences in the expression of 
Introduction
Bone marrow transplantation is an effective treatment for patients with leukemia, aplastic anemia, immunodeficiencies, and some disorders of metabolism. However, the weeks after the transplant are marked by abnormalities ofboth the cellular and humoral immune responses. These abnormalities are particularly severe in patients with graft vs. host disease (GvHD),' and they contribute to the morbidity and mortality from opportunistic infection. Defects in T "helper" (Th), T "suppressor", and B cells have been described (1-1 1); however, the relative importance of defects in each compartment of the immune response is as yet unclear.
We have previously observed that in some transplanted patients, a portion of the recovering B lymphocytes expresses an unusual pattern ofcell-surface antigens. These cells express Leu-1 (CD5) in addition to surface immunoglobulin, Leu-12 (CDl9), BI (CD20), and HLA-DR that are expressed on conventional circulating B lymphocytes (12) . B cells with this phenotype are observed in human chronic lymphocytic leukemia (13) and normal human fetal spleen and lymph nodes (14) (15) (16) . Leu-l B cells are a rare subset of B cells in normal adult humans (15, 17, 18) , but some B cells can apparently express Leu-1 when activated with lectins or phorbol esters (19) . A possibly analogous cell has been observed in neonatal, New Zealand black, and motheaten mice (Ly-l B cells) (20) (21) (22) . There are functional similarities and differences between human fetal spleen Leu-1+ B cells and murine Ly-l B cells. In the mouse these cells are constitutive producers of IgM that tend to have autoimmune reactivity, but do not proliferate or produce specific antibodies in response to lectins or to immunization (21) , and they augment the helper effects of suboptimal numbers of Th cells in a seccondary immune response (22) (23) (24) ; perhaps, in part due to the production of lymphokines (22, 25) . In human fetuses, Leu-lI B cells do not proliferate in response to lectins or constitutively produce IgM. However, they produce small amounts of IgM, but not IgG if adequate Th cells are present. Leu-lI B cells are incapable of augmenting suboptimal numbers of Th cells in a primary antibody response (14) . Based on the observation that Ly-l B cells do not appear after bone marrow grafting from adult mice unless peritoneal washout cells are infused, it has been suggested that in mice the Ly-l B cells are actually derived from a separate progenitor than conventional B lymphocytes, and that they may reflect a separate lineage of B lymphocytes (26) .
This report describes studies that were designed to determine the frequency of Leu-l+ B cells after human marrow grafting, their relationship to the recovery of the humoral immune response, and the effects of GvHD on the reconstitution of these cells.
Methods
Patients Table  I . Details of the regimens have been published previously (27) (28) (29) . In tionated total body irradiation (TBI) administered in six equal fractions over days -3-0. Patients with aplastic anemia received 0.2 ml/kg rabbit anti-thymocyte serum (ATS) on days -6, -4, and -2; 12.5 mg/kg procarbazine (PC) on days -7, -5, and -3; and 50 mg/kg CTX on days -5 through -2 as described previously (27) . Children with severe combined immunodeficiency syndrome (SCIDS) who received haploidentical grafts were treated similarly as patients with aplastic anemia, except they did not receive the PC. The patients with Wiskott-Aldrich and DiamondBlackfan syndromes received 3 mg/kg busulfan (Bu) on days -9 through -6 and 50 mg/kg CTX on days -5 through -2 in addition to ATS as described above. After two unsuccessful attempts the patient with osteopetrosis was successfully transplanted with marrow from an MHCincompatible donor after preparation with ATS, followed by TBI (500 rad in a single fraction) and an additional 600 rad to the spleen and left hemiabdomen, and 120 mg cyclosporine (CYA) twice a day. This was the only patient who received prophylactic CYA. 13 patients received marrows that had been depleted of T lymphocytes with murine monoclonal antibodies; 2, marrows treated with anti-T12 (CD6); and 11, with anti-Leu-l (CD5) and baby rabbit complement as previously described (29) . This group included eight patients who received histoincompatible transplants and five leukemic patients who received marrow from histocompatible donors. Two patients transplanted for acute leukemia were syngeneic with their donors.
Engraftment. Engraftment was defined as 2 500 granulocytes/mm3; reticulocytes, 2 1%; and/or platelets, . 20,000/mm3 without transfusion. All patients engrafted.f Mixed lymphohematopoietic chimerism was evaluated using restriction fragment length polymorphism (RFLP) analysis, as previously described (30) Immunofluorescence and flow cytometric analysis. We examined blood lymphocytes in 26 normal subjects and in 46 transplant patients at various times after recovery from marrow translant by multiparameter flow cytometry as described previously (12) . In brief, Erythrocytes were excluded from analysis by labeling leukocytes with an FITC-conjugated antibody to the pan-leukocyte antigen HLE1 (Becton-Dickinson & Co.), and percentages of cells measured in the experiments were adjusted accordingly (12) . Data were collected on 0.5 X 104-5 X 104 cells for each pair offluorescent labels. Wide-volume gates were used to be sure all lymphocytes were included, and the number ofmonocytes was determined by labeling the cells with the monocyte-specific monoclonal antibody, PE anti-Leu-M3 (Becton-Dickinson & Co. (34) .
Results
Immunofluorescence. As demonstrated in Fig Table II. tendency for the relative numbers of Leu-l+ cells to decline -1 yr after the transplant, but the data did not reach statistical significance (Table II, Fig. 3 ). Even longer than 1 yr after transplant, some patients continued to have absolute Leu-1 + B cells counts that were substantially higher than normal subjects (Table II) .
Effects of GvHD on recovery ofB lymphocytes. GvHD had a profound effect on the recovery of both classes of B cells (Fig.  3) . In the absence of GvHD there was prompt recovery of Leu To assess the patients for independent effects of acute and chronic GvHD, those with grades 2-4 acute GvHD were examined for B cell recovery in the 1st 3 mo after transplant since most acute GvHD occurs in that interval. In contrast to patients with grades 0-1 acute GvHD, patients with grades 2-4 acute GvHD had significantly fewer (P < 0.025) of both types of B cells (Table II (Table II) .
We examined the probability of recovery of Leu-l+ B cells in a life table analysis (Fig. 4) Relationship ofB cell subsets to serum immunoglobulin levels.
We examined the relationship between serum immunoglobulin levels, after 6 wk posttransplant, and numbers of circulating B lymphocytes. The serum IgG weakly correlated with the total number of B cells (logistic regression: r = 0.357, P < 0.01) as well as with each subset ofB cells (multivariate logistic regression: Leu-l+ B cells, r2 = 0.138, P < 0.01; and Leu-1-B cells, r2 = 0.129, P < 0.01). There was a similar weak correlation between total B cells and serum IgM (logistic regression: r = 0.379, P < 0.01), but analysis by Leu-I status failed to show a significant relationship. The same relationship was apparent when the patients were analyzed by chronic GvHD status. There was no correlation between either total B cells or either type of B cell with serum IgA levels.
Discussion
Several investigators have studied the recovery of the humoral immune response after bone marrow transplantation, and defects in the regulatory capabilities of T lymphocytes as well as deficiencies in the numbers and responses of B lymphocytes have been described (1-1 1) . There is general agreement that immunologic responsiveness in vivo and in vitro regenerates slowly in the months to years after marrow grafting and that the rate of recovery and loss of qualitative defects in both cellular and humoral responses are dependent to a large extent on the presence of GvHD. The generalized defects in immunity are largely responsible for the morbidity and mortality from late infection that is observed after marrow transplantation.
We have been particularly interested in an unusual population of B cells, that are prominent in many transplanted patients without GvHD. These B cells co-express the cell-surface antigen Leu-l (CD5) with more usual B cell-surface proteins HLA-DR, Leu-12, B1, IgM and IgD (12) . Although Leu-1 is primarily associated with T lymphocytes, B lymphocytes that express Leu-I have been described in man, in human fetal lymphoid organs, and in some malignant B cells (13) (14) (15) (16) (17) . However, in contrast to malignant Leu-lI B cells, Leu-I+ B cells that recover after marrow grafting are not monoclonal (12) and do not express IL-2R.
A murine antigen, Ly-1, is similar to human Leu-1, and a possibly analogous B cell population (Ly-l B cells) has been found in neonatal, New Zealand black, and motheaten mice, where they produce IgM and/or IgG3 that tends to have autoimmune reactivity (20) (21) (22) . Furthermore, Ly-I B cells do not respond to immunization with production of specific antibodies, and they may be able to provide allotypic and idiotypic helper cell function to suboptimal numbers of Th cells in a secondary immune response. It has been suggested that the tendency to produce anti-idiotype antibody and lymphokines is related to their possible function in the control of Ig synthesis (22) (23) (24) (25) . Numbers of Ly-l B cells diminish with the aging of mice (21) . Similar to the mouse, Leu-1 + B cells are prominent in the human fetus, but they become less numerous in adults. Leu-1 + B cells contrast with Ly-l B cells in that they only produce small amounts of IgM.
In our transplant patients there were no differences in B cell reconstitution that were dependent on the diagnoses or the pretransplant preparation between any of the groups we studied. The patients with aplastic anemia were no different from the patients with leukemia and other patients who received preparative therapy, which is generally considered to be toxic to stem cells. We were particularly interested in patients who did not receive "ablative" therapy since Hayakawa and co-workers (26) demonstrated chimeric Ly-l B cells in mice that had been irradiated with 500 rad, a radiation dose that may result in mixed hematopoietic as well as lymphoid chimerism (35) . Even though the transplant conditioning regimen we used for patients with aplastic anemia would not necessarily be expected to result in irreversible B cell injury, we have shown using RFLP analysis that the Leu-I' B cells in our patients were of donor origin and not monoclonal populations (12) .
There were too few children with severe combined immunodeficiency to say whether the known heterogeneity of B lymphocyte numbers in this syndrome was reflected in different numbers of Leu-1+ B cells after transplantation. It is conceivable that we would have observed different patterns ofB cell recovery in children in whom there were B cells before transplant in comparison with children with no preexistent B cells. We suspect that children with SCIDS who have no preexistent B cells will demonstrate the pattern ofB cell recovery seen in other disorders.
Although some of the patients received marrow that had been purged of Leu-l-bearing cells with anti-Leu-l and complement, we saw no difference in the rate of recovery or numbers of Leu-l+ B cells in these patients. Since Leu-l is expressed weakly on B cells, it is possible that a Leu-l B lymphocyte precursor escaped lysis or that the Leu-1 + B cell precursor does not express Leu-l . Hayakawa and colleagues have suggested that in the mouse, Ly-I+ B cells and conventional Ly-I-B cells are derived from separate precursors. This contention was supported by the observation that reconstitution ofblood Ly-I' B cells did not occur ifthe mice were transplanted with adult murine bone marrow alone. Ifperitoneal washout cells were added or marrow from neonatal mice was used, Ly-1 + B cells are regenerated normally (26 The function of the Leu-l antigen on the surface of these cells is unknown. It has been suggested that anti-CD5 antibodies increase the secretion ofinterleukin 2 (IL-2) (37-39). Preliminary observations suggest that the proliferative responses of partially purified populations of B cells are augmented in the presence of anti-Leu-l; perhaps, due to the division of residual T cells stimulated by endogenous IL-2 or to augmented T cell-dependent, lectin-induced B cell blastogenesis in the presence of IL-2 (unpublished observations). It has been demonstrated that a variety of stimuli including lectins, EBV (40) , and Staphylococcus aureus Cowan I (41) can cause IL-2R expression on normal B cells. We were unable to demonstrate IL-2R on either population of B cell by using the monoclonal antibody anti-IL-2R. It is possible that IL-2R are present and functional at a cell-surface density that cannot be detected on the FACS, however, prior studies of IL-2R expression on normal B cells indicated that there is usually adequate surface expression to detect it by our technique (40, 41) . If Leu-1 expression denotes non-specific activation of B cells, we would expect IL-2R expression in these cells as well. We were unable to detect IL-2R expression on either human fetal Leu-1 + B cells (unpublished observations) or on Leu-I + B cells that appeared after transplantation. Note that although IL-2R expression tends to persist after EBV transformation of IL-2R' B cells (40), we were unable to detect Leu-l after transformation of Leu-lI B cells. It is possible that Leu-l+ B cells were infected with EBV and subsequently stopped expressing Leu-1, or Leu-1+ B cells are not transformable with EBV; however, Leu-1 clearly was not expressed in a situation where the cells were dividing rapidly. Although in some patients there may have been spontaneous proliferation ofLeu-1 + B cells (unpublished observations), which was not a uniform finding, and in the absence of IL-2R expression, our results suggest that Leu-1 expression does not reflect non-specific activation ofthese cells.
The role of Leu-l+ B cells in the ontogeny of the normal human humoral immune response is also unknown. It is tempting to infer that the recovery ofimmune cells after bone marrow transplantation in part recapitulates fetal ontogeny. Indeed, although normal adults have very few Leu-1I B cells (generally -1% of circulating lymphocytes and < 5% of splenic lymphocytes (14) in adults), they are a major population of B lymphocytes in human fetal spleen and in the peripheral blood ofadults and children after bone marrow transplantation. In did not correlate at all. In patients without chronic GvHD, immunoglobulin levels were generally well maintained at or slightly below the normal range. In contrast, patients with chronic GvHD tended to become hypogammaglobulinemic, although individual patients with severe prolonged chronic GvHD may become hypergammaglobulinemic (7, 10) . The weak correlation between numbers of Leu-1+ B cells and maintenance of normal levels of IgG persisted even when analyzed according to the presence or absence of chronic GvHD, however, it was clear from the low value of the correlation coefficients that we did not identify the majority of factors that were responsible for most of the variability of Ig levels. Although both Leu-lI and Leu-I-B cells are present in large numbers in the blood after marrow grafting, the proportion ofthese cells in lymph nodes and spleen, where most antigens are processed, has not been determined. In the human fetus Leu-1 + B cells are prominent in the follicles in association with Th cells and follicular dendritic cells (15, 16 ). We have not been able to demonstrate Leu-l-mediated helper activity in normal adults or human fetal spleen in a primary immune response, and the ability of these cells to provide helper activity in a secondary immune response has not been assessed. It is appealing to speculate that the mechanism by which patients are able to maintain IgG levels in the absence of normal Th cell numbers or activity is in part mediated through Leu-II B cells.
